Effect of macrovescicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation

被引:113
作者
Zamboni, F [1 ]
Franchello, A [1 ]
David, E [1 ]
Rocca, G [1 ]
Ricchiuti, A [1 ]
Lavezzo, B [1 ]
Rizzetto, M [1 ]
Salizzoni, M [1 ]
机构
[1] Molinette Mauriziano Hosp, Liver Transplantat Ctr, I-10126 Turin, Italy
关键词
liver; steatosis; transplantation;
D O I
10.1034/j.1399-0012.2001.150109.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
The influence of steatosis and of other donor and recipient characteristics in affecting liver performance post-orthotopic liver transplantation (OLT) was evaluated in 311 consecutive liver transplantations made in 278 patients. Donor variables considered were age, sex, blood group, cause of death, intensive care unit (ICU) days, need for vasopressors. hepatic enzymes and bilirubin, total and warm ischemia time, and macro- and microvescicular steatosis. Recipient variables considered were age, sex, blood group, biliary output, and post-OLT peak levels of hepatic enzymes. Patient and graft survival were the main outcome indicators. In the multivariate analysis, macrovescicular steatosis involving 25% or more of the hepatocytes was the only variable independently associated with shorter patient survival (p < 0.05). Five (62.5%) of the eight livers with macrovescicular steatosis involving 25% or more of the hepatocytes incurred in a delayed non-function (DNF) and one (12.5%) in a primary non-function (PRNF). The incidence of DNF and PRNF in the group with macrovescicular steatosis involving less than 25% of the liver cells was 1.6% (p < 0.001) and 2.3%, respectively. Microvescicular steatosis of any degree was not associated with a worse prognosis. Macrovescicular steatosis involving 25% or more of the hepatocytes identifies marginal livers, the use of which significantly increases the risk of graft non-function post-OLT.
引用
收藏
页码:53 / 57
页数:5
相关论文
共 20 条
[1]   THE USE OF MARGINAL DONORS FOR ORGAN-TRANSPLANTATION - THE INFLUENCE OF DONOR AGE ON OUTCOME [J].
ALEXANDER, JW ;
VAUGHN, WK .
TRANSPLANTATION, 1991, 51 (01) :135-141
[2]   Influence of donor and recipient gender on the outcome of liver transplantation [J].
Brooks, BK ;
Levy, MF ;
Jennings, LW ;
Abbasoglu, O ;
Vodapally, M ;
Goldstein, RM ;
Husberg, BS ;
Gonwa, TA ;
Klintmalm, GB .
TRANSPLANTATION, 1996, 62 (12) :1784-1787
[3]  
BUCHEL I, 1993, TRANSPLANT P, V25, P1558
[4]   THE PREDICTIVE VALUE OF DONOR LIVER BIOPSIES FOR THE DEVELOPMENT OF PRIMARY NONFUNCTION AFTER ORTHOTOPIC LIVER-TRANSPLANTATION [J].
DALESSANDRO, AM ;
KALAYOGLU, M ;
SOLLINGER, HW ;
HOFFMANN, RM ;
REED, A ;
KNECHTLE, SJ ;
PIRSCH, JD ;
HAFEZ, GR ;
LORENTZEN, D ;
BELZER, FO .
TRANSPLANTATION, 1991, 51 (01) :157-163
[5]   Assessing risk in liver transplantation - Special reference to the significance of a positive cytotoxic crossmatch [J].
Doyle, HR ;
Marino, IR ;
Morelli, F ;
Doria, C ;
Aldrighetti, L ;
McMichael, J ;
Martell, J ;
Gayowski, T ;
Starzl, TE .
ANNALS OF SURGERY, 1996, 224 (02) :168-177
[6]   Safe use of hepatic allografts from donors older than 70 years [J].
Emre, S ;
Schwartz, ME ;
Altaca, G ;
Sethi, P ;
Fiel, MI ;
Guy, SR ;
Kelly, DM ;
Sebastian, A ;
Fisher, A ;
Eickmeyer, D ;
Sheiner, PA ;
Miller, CM .
TRANSPLANTATION, 1996, 62 (01) :62-65
[7]   Use of livers with microvesicular fat safely expands the donor pool [J].
Fishbein, TM ;
Fiel, MI ;
Emre, S ;
Cubukcu, O ;
Guy, SR ;
Schwartz, ME ;
Miller, CM ;
Sheiner, PA .
TRANSPLANTATION, 1997, 64 (02) :248-251
[8]   INHIBITION OF MITOCHONDRIAL BETA-OXIDATION AS A MECHANISM OF HEPATOTOXICITY [J].
FROMENTY, B ;
PESSAYRE, D .
PHARMACOLOGY & THERAPEUTICS, 1995, 67 (01) :101-154
[9]  
GREIG PD, 1990, TRANSPLANT P, V22, P2072
[10]  
HOOFNAGLE JH, 1996, HEPATOLOGY, V24, P86